Associate Professor; Titus Family Department of Clinical Pharmacy and Pharmacoeconomics and Policy
Early in her career, her research interests included the development of an immunoassay for gynecological cancers and an understanding of the process of peritoneal healing and the formation of intraperitoneal adhesions. After identification of key processes in these healing events, one focus became the identification of therapeutic interventions, both devices and pharmaceuticals, by which adhesions can be prevented. This led to her current interest in pharmaceutical development. In the 80s, she discovered that molecules generated by the renin angiotensin system have potential therapeutic benefit. The current focus of her basic science research is the cellular and molecular mechanisms by which angiotensin peptides accelerated tissue regeneration and the development of small molecule agonists of the protective arm of this system. Studies have shown that there is a primary effect on adult stem cell proliferation and homing. Most recently, her basic research has developed to the point that eight clinical trials involving the molecules developed through her research have been initiated with one molecule in Phase III trials and one in Phase II trials (one completed and one ongoing). Current areas of therapeutic development include dermal injuries (diabetic wounds, incisional wounds and radiation induced injuries), diabetes (multi-organ failure), improved healing of ocular injuries and progressive degenerative diseases of the muscular and nervous systems. The latter two areas of research are a focus of the USC Institute for Biomedical Therapeutics.
Kathleen E. Rodgers, PhD, is an Associate Professor in the Titus Family Department of Clinical Pharmacy and Pharmaceutical Economics & Policy in the School of Pharmacy at the University of Southern California. Throughout her career, Dr. Rodgers has conducted research into a broad array of topics including gynecological cancers, medical device safety, drug effectiveness and toxicology. Since joining USC in 1986, she has been interested in applied research. There is an expertise within her laboratory in development of animal models relevant to surgical injuries and to provide and conduct developmental plans to optimized product delivery and efficacy. As her focus has been to provide translational assistance from the bench to the patient, she has spent time consulting for companies interested in developing products within her areas of expertise as well as has served on teams to further the development of exciting innovations of fellow professors. Further, she has developed recommended panels of safety studies to allow conduct of clinical trials under FDA and EU supervision. She has participated in the development of over twenty five therapies that are either marketed or in clinical development.
List of Publications:
- Rodgers, KE, Peterson, KJ, Maulhardt, HA and diZerega, GS. Multilineage Hematopoietic Recovery following Angiotensin (1-7) Administration, Expert Opinion in Investigational Drugs, 23(4):551-9, 2014. doi: 10.1517/13543784.2014.891015. Epub 2014 Feb 20. PMID: 24555825
- Rodgers, KE. Preclinical and clinical development of angiotensin peptides (Mas/Ang(1-7)/ACE-2): Future Clinical Applications. Protective Arm of the Renin Angiotensin System, Elsevier Press, in press.
- Rodgers, KE. NorLeu3-Angiotensin 1-7 As a Potent Regenerative Therapy for the Healing of Diabetic Foot Ulcers. Advances in Wound Care (2015 Forum Issue). Theme: Topical Therapeutics in Wound Healing: New and Old. Editors: Wei Li and Kathy Rodgers, in press.
- Jadhav SS, Espinoza T, Roda N, Meeks C, Mordwinkin N, Hill C, Louie SG and Rodgers KE. Effects of Combined Radiation and Thermal Injury on Apoptosis and Inflammation. Apoptosis, in press.
- 1976-1980 B.S. University of California, Irvine, Biology, with a concentration in Cell Biology
- 1981-1984 Ph.D., University of California, Riverside, Biomedical Sciences, Organophosphorus Immunotoxicity
Other web profiles: